Scarica l'app Stockscreener
1.15
5.74%
-0.07
Pre-mercato:
1.14
-0.01
-0.87%
Precedente Chiudi:
$1.22
Aprire:
$1.18
Volume 24 ore:
758.96K
Relative Volume:
1.14
Capitalizzazione di mercato:
$72.55M
Reddito:
$139.77M
Utile/perdita netta:
$-97.62M
Rapporto P/E:
-0.7278
EPS:
-1.58
Flusso di cassa netto:
$-61.71M
1 W Prestazione:
-22.30%
1M Prestazione:
-49.56%
6M Prestazione:
-67.61%
1 anno Prestazione:
-91.59%
Intervallo 1D:
$1.10
$1.19
Intervallo di 1 settimana:
$1.10
$1.51
Portata 52W:
$1.10
$19.54
Macrogenics Inc Stock (MGNX) Company Profile
Nome
Macrogenics Inc
Settore
Industria
Telefono
301-251-5172
Indirizzo
9704 MEDICAL CENTER DRIVE, Rockville, MD
Confronta MGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.15 | 72.55M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-07 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-31 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-05-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Downgrade | Stifel | Buy → Hold |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2024-04-26 | Iniziato | B. Riley Securities | Buy |
| 2024-04-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-03-04 | Reiterato | BTIG Research | Buy |
| 2024-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-22 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-11-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-02-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-04 | Iniziato | SMBC Nikko | Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Aggiornamento | Barclays | Underweight → Overweight |
| 2020-12-22 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-03 | Downgrade | Citigroup | Buy → Neutral |
| 2020-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2019-12-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Guggenheim | Neutral |
| 2019-02-07 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-02-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-02-06 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Downgrade | Citigroup | Neutral → Sell |
| 2018-12-10 | Downgrade | Raymond James | Outperform → Underperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-05-31 | Iniziato | Evercore ISI | Outperform |
| 2018-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-31 | Iniziato | Raymond James | Outperform |
Mostra tutto
Macrogenics Inc Borsa (MGNX) Ultime notizie
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Has $540,000 Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
HC Wainwright Increases Earnings Estimates for MacroGenics - Defense World
MacroGenics, Inc. (MGNX) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
MacroGenics (NASDAQ:MGNX) Price Target Lowered to $2.00 at HC Wainwright - Defense World
MGNX stock touches 52-week low at $1.88 amid market challenges - Investing.com Australia
MGNX stock touches 52-week low at $1.88 amid market challenges By Investing.com - Investing.com South Africa
MacroGenics stock target cut to $2 at H.C. Wainwright By Investing.com - Investing.com Canada
Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical - openPR.com
Macrogenics Inc (NASDAQ: MGNX) Analysts Prediction On How Much It Could Rise - Stocks Register
MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Consensus Price Target from Analysts - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2024 Earnings Call Transcript - Insider Monkey
MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook - Investing.com Canada
StockNews.com Downgrades MacroGenics (NASDAQ:MGNX) to Hold - Defense World
MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook By Investing.com - Investing.com South Africa
MacroGenics Inc’s 2024 Earnings Call Highlights - TipRanks
MacroGenics axes ADC drug following Phase II failure in prostate cancer - Yahoo
Macrogenics Inc (MGNX) Q4 2024: Everything You Need to Know Ahea - GuruFocus.com
Stifel maintains Hold on MacroGenics stock, price target at $6 By Investing.com - Investing.com Canada
Citizens JMP maintains MacroGenics stock with Market Outperform By Investing.com - Investing.com South Africa
Citizens JMP maintains MacroGenics stock with Market Outperform - Investing.com India
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates - MSN
MacroGenics Reports 2024 Financial Results and Progress - TipRanks
Macrogenics Inc (MGNX) Q4 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses - Yahoo Finance
MacroGenics (MGNX) Q4 2024 Earnings Call Transcript - Yahoo
MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
MACROGENICS Earnings Results: $MGNX Reports Quarterly Earnings - Nasdaq
Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations - Investing.com India
Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations By Investing.com - Investing.com UK
MacroGenics Inc. (MGNX) reports earnings - Quartz
MacroGenics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MacroGenics Inc Provides Update On Corporate Progress And 2024 Financial Results - Marketscreener.com
Macrogenics Inc (MGNX) Reports Q4 Revenue of $150 Million, Surpa - GuruFocus
MACROGENICS INC SEC 10-K Report - TradingView
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results - GlobeNewswire
MacroGenics Triples Revenue to $150M as Cancer Drug Pipeline Advances - StockTitan
MGNX stock touches 52-week low at $2.15 amid sharp annual decline - Investing.com Australia
Macrogenics Stock Drops 77% After Study Deaths - The Wall Street Journal
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
MacroGenics (MGNX) to Release Quarterly Earnings on Thursday - Defense World
MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships By Investing.com - Investing.com South Africa
MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships - Investing.com
MGNX Deadline: MGNX Investors with Losses in Excess of $100K Hav - GuruFocus.com
MacroGenics at Leerink’s Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
MacroGenics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before September 24, 2024 to Discuss Your RightsMGNX - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Macrogenics Inc Azioni (MGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):